The recent pandemic has made all levels of physicians’ lives even more stressful than before, especially with respect to dealing with an ongoing increase in conditions of general systemic inflammation. We hope this information can help your patients – if they wish to take action – under your guidance.*

Peskin Pharmaceuticals^® follows the new medicament paradigm. Instead of treating diseases/disorders by blocking/impeding and “managing” the illness’ progression, our focus is reversing and optimizing the resolution of the underlying disease/disorder. Once inflammation is reduced, healing accelerates naturally. Until now, there has not been a medicament designed to naturally and safely resolve inflammation by maximizing the production of prostaglandin PGE1. EZTREK^™ is the new adjuvant medical food – compensating for an impaired delta-6 desaturase metabolic pathway – the medical profession has been lacking.

Systemic inflammation is a part of many intractable diseases, including cancer, CVD, diabetes, arthritis – to name a few. Compensating for an impaired delta-6 desaturase metabolic pathway is fundamental and required to successfully reverse the underlying etiology of these diseases/disorders. Once inflammation is reduced, healing accelerates naturally. EZTREK^™ is the clinical culmination of this groundbreaking science.

Our unique focus is compensating for an impaired delta-6 desaturase (D6D) metabolic pathway – maximizing PGE1 production to decrease inflammation. No modality of patient treatment can be maximized without also optimizing patients’ EFA-based metabolic pathways; in particular, D6D and PGE1.

Introduction